BRIEF—HiFiBiO Therapeutics attracts $37.5 million series B investment

HiFiBiO Therapeutics, a biotech startup with offices in China, France and the USA, has won $37.5m in a series B round led by Sequoia China and LYFE Capital.

The firm says it will use the cash to develop its pipeline of antibody drugs to treat cancer and autoimmune disorders.

Sequoia China managing director Lynn Yang said HiFiBiO’s “unique combination of deep-rooted biological expertise and truly disruptive single-B-cell cloning technology,” attracted her firm to the deal.